Cargando…

Pre-Existing Liver Disease and Toxicity of Antifungals

Pre-existing liver disease in patients with invasive fungal infections further complicates their management. Altered pharmacokinetics and tolerance issues of antifungal drugs are important concerns. Adjustment of the dosage of antifungal agents in these cases can be challenging given that current ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Spernovasilis, Nikolaos, Kofteridis, Diamantis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309049/
https://www.ncbi.nlm.nih.gov/pubmed/30544724
http://dx.doi.org/10.3390/jof4040133
_version_ 1783383328347389952
author Spernovasilis, Nikolaos
Kofteridis, Diamantis P.
author_facet Spernovasilis, Nikolaos
Kofteridis, Diamantis P.
author_sort Spernovasilis, Nikolaos
collection PubMed
description Pre-existing liver disease in patients with invasive fungal infections further complicates their management. Altered pharmacokinetics and tolerance issues of antifungal drugs are important concerns. Adjustment of the dosage of antifungal agents in these cases can be challenging given that current evidence to guide decision-making is limited. This comprehensive review aims to evaluate the existing evidence related to antifungal treatment in individuals with liver dysfunction. This article also provides suggestions for dosage adjustment of antifungal drugs in patients with varying degrees of hepatic impairment, after accounting for established or emerging pharmacokinetic–pharmacodynamic relationships with regard to antifungal drug efficacy in vivo.
format Online
Article
Text
id pubmed-6309049
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63090492019-06-17 Pre-Existing Liver Disease and Toxicity of Antifungals Spernovasilis, Nikolaos Kofteridis, Diamantis P. J Fungi (Basel) Review Pre-existing liver disease in patients with invasive fungal infections further complicates their management. Altered pharmacokinetics and tolerance issues of antifungal drugs are important concerns. Adjustment of the dosage of antifungal agents in these cases can be challenging given that current evidence to guide decision-making is limited. This comprehensive review aims to evaluate the existing evidence related to antifungal treatment in individuals with liver dysfunction. This article also provides suggestions for dosage adjustment of antifungal drugs in patients with varying degrees of hepatic impairment, after accounting for established or emerging pharmacokinetic–pharmacodynamic relationships with regard to antifungal drug efficacy in vivo. MDPI 2018-12-10 /pmc/articles/PMC6309049/ /pubmed/30544724 http://dx.doi.org/10.3390/jof4040133 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Spernovasilis, Nikolaos
Kofteridis, Diamantis P.
Pre-Existing Liver Disease and Toxicity of Antifungals
title Pre-Existing Liver Disease and Toxicity of Antifungals
title_full Pre-Existing Liver Disease and Toxicity of Antifungals
title_fullStr Pre-Existing Liver Disease and Toxicity of Antifungals
title_full_unstemmed Pre-Existing Liver Disease and Toxicity of Antifungals
title_short Pre-Existing Liver Disease and Toxicity of Antifungals
title_sort pre-existing liver disease and toxicity of antifungals
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309049/
https://www.ncbi.nlm.nih.gov/pubmed/30544724
http://dx.doi.org/10.3390/jof4040133
work_keys_str_mv AT spernovasilisnikolaos preexistingliverdiseaseandtoxicityofantifungals
AT kofteridisdiamantisp preexistingliverdiseaseandtoxicityofantifungals